Skip to main content

UroGen Pharma Ltd 8-K, filed Nov 4, 2026

UroGen Pharma Ltd. (URGN)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

UroGen Pharma Ltd filed this 8-K on November 4, 2026.

UroGen reported $68.0 million in third-quarter ZUSDURI revenue, up 35% from the second quarter of 2026, as the FDA accepted UGN-103's NDA for review with a June 14, 2027 PDUFA target date. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits